Literature DB >> 26439919

The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region.

Chiara de Waure1, Francesco Di Nardo2, Walter Mazzucco3, Darko Nedovic4, Mario Alberto Battaglia5, Vincenzo Busillo6, Walter Di Iorio7, Antonio Gallo8, Roberta Lanzillo9, Emilio Lombardi10, Giorgia Teresa Maniscalco11, Giuseppe Orefice9, Maria Petracca9, Felice Romano12, Leonardo Sinisi13, Anna Pia Spadera8, Daniele Spitaleri14, Pasquale Vivo15, Walter Ricciardi1.   

Abstract

This cross-sectional study has investigated the diagnostic and therapeutic management of patients suffering from multiple sclerosis (MS) in the Campania Region (Italy). A survey involving all the reference centers for MS in Campania Region was conducted from March to August 2011. Centers responded to a web-administered questionnaire on management and clinical characteristics of MS patients. In the study period, 3263 patients (mean age 37 years, 66 % females) accessed the centers. Patients received a first diagnosis of MS in 161 cases (4.9 %). About 37 % of the subjects without a previous diagnosis came to the centers on their own initiative. All patients underwent a complete neurological examination and expanded disability status scale. The other most common investigations were magnetic resonance imaging (44.0 %) and evoked potentials (22.1 %). The number of treated patients was 2797 (87.1 %). The most used drugs were interferon β and glatiramer acetate. The time between diagnosis and initiation of therapy exceeded 6 months in 32 % of cases. Second-line drugs were under-used: 16 % of patients who might benefit from them show high clinical and radiological disease activity despite treatment with immunomodulant drugs. The MS care management of the surveyed centers showed consistent margins for improvement in 2011. Even though these data do not represent the current situation, they can be used to monitor improvements in MS care.

Entities:  

Keywords:  Disease management; Health services needs and demand; Multiple sclerosis

Mesh:

Year:  2015        PMID: 26439919     DOI: 10.1007/s10072-015-2389-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  13 in total

1.  The cost of delaying treatment in multiple sclerosis: what is lost is not regained.

Authors:  S R Schwid; C T Bever
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

2.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

Authors:  B K Kleinschmidt-DeMasters; Kenneth L Tyler
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

Review 3.  Multiple sclerosis: geoepidemiology, genetics and the environment.

Authors:  Ron Milo; Esther Kahana
Journal:  Autoimmun Rev       Date:  2009-11-20       Impact factor: 9.754

Review 4.  Screening for disease.

Authors:  W C Black; H G Welch
Journal:  AJR Am J Roentgenol       Date:  1997-01       Impact factor: 3.959

5.  New multiple sclerosis phenotypic classification.

Authors:  Fred D Lublin
Journal:  Eur Neurol       Date:  2014-09-26       Impact factor: 1.710

6.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors:  G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

7.  Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis.

Authors:  Daniel S Bandari; Debora Sternaman; Theodore Chan; Chris R Prostko; Tamar Sapir
Journal:  J Manag Care Pharm       Date:  2012 Nov-Dec

8.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910

View more
  2 in total

1.  The most important psychological and psychosocial needs of Polish multiple sclerosis patients and their significant others.

Authors:  Andrzej Potemkowski; Waldemar Brola; Anna Ratajczak; Marcin Ratajczak; Mariusz Kowalewski; Małgorzata Lewita; Katarzyna Kapica-Topczewska; Joanna Tarasiuk; Adam Stępień; Katarzyna Gocyła-Dudar; Jacek Zaborski; Halina Bartosik-Psujek
Journal:  Neuropsychiatr Dis Treat       Date:  2017-07-12       Impact factor: 2.570

2.  Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery.

Authors:  Marcello Moccia; Andrea Tajani; Rosa Acampora; Elisabetta Signoriello; Guido Corbisiero; Adriano Vercellone; Primo Sergianni; Francesca Pennino; Roberta Lanzillo; Raffaele Palladino; Antonio Capacchione; Vincenzo Brescia Morra; Giacomo Lus; Maria Triassi
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.